{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T22:29:39Z","timestamp":1773268179066,"version":"3.50.1"},"reference-count":39,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,1,23]],"date-time":"2008-01-23T00:00:00Z","timestamp":1201046400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2008,3]]},"abstract":"<jats:sec><jats:title>Background and Objectives<\/jats:title><jats:p>Combination antiretroviral therapy (cART) is changing, and this may affect the type and occurrence of side effects. We examined the frequency of lipodystrophy (LD) and weight changes in relation to the use of specific drugs in the Swiss HIV Cohort Study (SHCS).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In the SHCS, patients are followed twice a year and scored by the treating physician as having \u2018fat accumulation\u2019, \u2018fat loss\u2019, or neither. Treatments, and reasons for change thereof, are recorded. Our study sample included all patients treated with cART between 2003 and 2006 and, in addition, all patients who started cART between 2000 and 2003.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>From 2003 to 2006, the percentage of patients taking stavudine, didanosine and nelfinavir decreased, the percentage taking lopinavir, nevirapine and efavirenz remained stable, and the percentage taking atazanavir and tenofovir increased by 18.7 and 22.2%, respectively.<\/jats:p><jats:p>In life\u2010table Kaplan\u2013Meier analysis, patients starting cART in 2003\u20132006 were less likely to develop LD than those starting cART from 2000 to 2002 (<jats:italic>P<\/jats:italic>&lt;0.02). LD was quoted as the reason for treatment change or discontinuation for 4% of patients on cART in 2003, and for 1% of patients treated in 2006 (<jats:italic>P<\/jats:italic> for trend &lt;0.001). In univariate and multivariate regression analysis, patients with a weight gain of \u22655\u2003kg were more likely to take lopinavir or atazanavir than patients without such a weight gain [odds ratio (OR) 2, 95% confidence interval (CI) 1.3\u20132.9, and OR 1.7, 95% CI 1.3\u20132.1, respectively].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>LD has become less frequent in the SHCS from 2000 to 2006. A weight gain of more than 5\u2003kg was associated with the use of atazanavir and lopinavir.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2007.00537.x","type":"journal-article","created":{"date-parts":[[2008,2,18]],"date-time":"2008-02-18T02:14:56Z","timestamp":1203300896000},"page":"142-150","source":"Crossref","is-referenced-by-count":54,"title":["Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000\u20132006"],"prefix":"10.1111","volume":"9","author":[{"given":"A","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Calmy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Schiffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Battegay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Opravil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u2010M","family":"Evison","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PE","family":"Tarr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Perneger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Hirschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Swiss HIV Cohort Study","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,1,23]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"22","article-title":"Decline in the AIDS and death rates in the EuroSIDA study","volume":"362","author":"Mocroft A","year":"2003","journal-title":"an observational study"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-005-0006-6"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra025261"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041811"},{"issue":"1","key":"e_1_2_5_6_2","first-page":"S141","article-title":"HIV lipodystrophy","volume":"17","author":"Carr A.","year":"2003","journal-title":"risk factors, pathogenesis, diagnosis and management"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00003"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001432-200402000-00005"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000214811.72916.67"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2006.20.6"},{"key":"e_1_2_5_11_2","first-page":"1482","article-title":"Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection","volume":"31","author":"Thi\u00e9baut R","year":"2000","journal-title":"Aquitaine Cohort, France, 1999"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)63513-1"},{"key":"e_1_2_5_13_2","first-page":"2093","article-title":"Diagnosis, prediction, and natural course of HIV\u20101 protease\u2010inhibitor\u2010associated lipodystrophy, hyperlipidaemia, and diabetes mellitus","volume":"353","author":"Carr A","year":"1999","journal-title":"a cohort study"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199815000-00001"},{"key":"e_1_2_5_15_2","first-page":"592","article-title":"Risk of lipodystrophy in HIV\u20101\u2010infected patients treated with protease inhibitors","volume":"357","author":"Martinez E","year":"2001","journal-title":"a prospective cohort study"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1086\/514639"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2003.06.002"},{"key":"e_1_2_5_18_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/135965350200700306","article-title":"Evaluation of the risk factors associated with lipodystrophy development in a cohort of HIV\u2010positive patients","volume":"7","author":"Seminari E","year":"2002","journal-title":"Antivir Ther"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2.3.429"},{"key":"e_1_2_5_20_2","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1177\/135965350601100202","article-title":"In combination, nucleoside reverse transcriptase inhibitors have significant effects on 3T3\u2010L1 adipocyte lipid accumulation and survival","volume":"11","author":"Kosmiski LA","year":"2006","journal-title":"Antivir Ther"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200202010-00002"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200109280-00009"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200210180-00005"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199709000-00008"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08094-7"},{"key":"e_1_2_5_26_2","first-page":"2251","article-title":"Lipodystrophy defined by a clinical score in HIV\u2010infected men on highly active antiretroviral therapy","volume":"13","author":"Christeff N","year":"1999","journal-title":"correlation between dyslipidaemia and steroid hormone alterations"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.86.2.504"},{"key":"e_1_2_5_28_2","first-page":"3","article-title":"Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy","volume":"9","author":"Mallon PW.","year":"2007","journal-title":"AIDS Rev"},{"key":"e_1_2_5_29_2","first-page":"50","article-title":"Abnormalities of body fat distribution in HIV\u2010infected persons treated with antiretroviral drugs","volume":"31","author":"Bernasconi E","year":"2002","journal-title":"The Swiss HIV Cohort Study"},{"key":"e_1_2_5_30_2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/135965350501000105","article-title":"Body fat changes among antiretroviral\u2010naive patients on PI\u2010 and NNRTI\u2010based cART in the Swiss HIV cohort study","volume":"10","author":"Young J","year":"2005","journal-title":"Antivir Ther"},{"key":"e_1_2_5_31_2","first-page":"387","article-title":"The Swiss HIV Cohort Study","volume":"39","author":"Ledergerber B","year":"1994","journal-title":"rationale, organization and selected baseline characteristics"},{"key":"e_1_2_5_32_2","unstructured":"SHCS website available at:http:\/\/www.shcs.ch"},{"issue":"1","key":"e_1_2_5_33_2","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.2337\/diacare.27.2007.S15","article-title":"Standards of medical care in diabetes","volume":"27","author":"American Diabetes Association.","year":"2004","journal-title":"Diabetes Care"},{"key":"e_1_2_5_34_2","first-page":"827","article-title":"Treatment for adult HIV infection","volume":"296","author":"Hammer SM","year":"2006","journal-title":"2006 recommendations of the International AIDS Society-USA panel"},{"key":"e_1_2_5_35_2","first-page":"191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral\u2010naive patients","volume":"292","author":"Gallant JE","year":"2004","journal-title":"a 3-year randomized trial"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200305020-00005"},{"key":"e_1_2_5_37_2","unstructured":"CDC\u2010NHANES available at:http:\/\/www.cdc.gov\/nchs\/nhanes.htm(accessed 28 June 2007)"},{"key":"e_1_2_5_38_2","first-page":"207","article-title":"Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy","volume":"288","author":"Carr A","year":"2002","journal-title":"a randomized trial"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000247574.33998.03"},{"key":"e_1_2_5_40_2","first-page":"726","article-title":"An objective case definition of lipodystrophy in HIV\u2010infected adults","volume":"361","author":"Carr A","year":"2003","journal-title":"a case\u2013control study"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2007.00537.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2007.00537.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T18:38:23Z","timestamp":1696876703000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2007.00537.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,1,23]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["10.1111\/j.1468-1293.2007.00537.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2007.00537.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,1,23]]}}}